Who is sponsoring NCT05392257?

NCT05392257 is sponsored by Qingdao Central Hospital.

What drugs are being tested in NCT05392257?

Interventions in NCT05392257: Rituximab + zanubrutinib + lenalidomide.

What condition does NCT05392257 study?

NCT05392257 studies Overall Survival.

Is NCT05392257 still recruiting?

NCT05392257 is currently status unknown. Last updated 26 May 2022.

Last reviewed 2022-05-26 · How we verify

NCT05392257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Status unknown Phase 2 Last updated 26 May 2022

What this trial tests

Phase 2 trial testing Rituximab + zanubrutinib + lenalidomide in Overall Survival in 20 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
1 May 2024

1 May 2024

Quick facts

Lead sponsor	Qingdao Central Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 May 2022
Primary completion	1 May 2024
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

Rituximab + zanubrutinib + lenalidomide — full drug profile →

Conditions studied

Overall Survival — all drugs for Overall Survival →

Sponsor

Qingdao Central Hospital

Who can join

Adults 18 to 80, any sex, with Overall Survival. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Zhang X, Chen K, Wang H, Deng X, et al · · 2023

Verify or expand the search:

Other recruiting trials for Overall Survival

Currently open trials in the same condition.

NCT07258043 — Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia · recruiting
NCT06527001 — Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer · active not recruiting
NCT06215495 — A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial · NA · recruiting
NCT05024175 — Long-term Follow-up of Subjects Treated With CAR T Cells · recruiting
NCT05477797 — Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma. · NA · recruiting

Other Qingdao Central Hospital trials

Trials by the same sponsor.

NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
NCT07090031 — Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting
NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT06500234 — Nutrition Impact on Immunotherapy of Cancer · Phase 3 · recruiting
NCT06514118 — Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05392257 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingdao Central Hospital
Last refreshed: 26 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05392257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing